Results 131 to 140 of about 29,210 (297)
FEBS Letters, Volume 599, Issue 20, Page 2878-2895, October 2025.In lymphoid organs, antigen recognition and B cell receptor signaling rely on integrins and the cytoskeleton. Integrins act as mechanoreceptors, couple B cell receptor activation to cytoskeletal remodeling, and support immune synapse formation as well as antigen extraction.
Abhishek Pethe, Tanja Nicole Hartmann
wiley +1 more source
Blood Neoplasia: Hypertension is a common side effect of Bruton tyrosine kinase inhibitors (BTKis). The second-generation BTKi zanubrutinib has high BTK selectivity, which may minimize off-target effects.
June-Wha Rhee +6 more
doaj +1 more source
FEBS Letters, Volume 599, Issue 20, Page 2854-2877, October 2025.B cells sense external mechanical forces and convert them into biochemical signals through mechanotransduction. Understanding how malignant B cells respond to physical stimuli represents a groundbreaking area of research. This review examines the key mechano‐related molecules and pathways in B lymphocytes, highlights the most relevant techniques to ...
Marta Sampietro +2 more
wiley +1 more source
BTK inhibitor ibrutinib in CLL and mantle cell lymphoma [PDF]
, 2013 Jame Abraham, Matt Stenger
openalex +1 more source
Five years of ibrutinib in CLL [PDF]
Blood, 2018 The study by Ahn et al in this issue of Blood is an important clinical update with a 5-year follow-up on efficacy and toxicity of single-agent ibrutinib, an inhibitor of B-cell receptor (BCR) pathway–associated Bruton tyrosine kinase (BTK), in patients with chronic lymphocytic leukemia (CLL ...
openaire +3 more sources
Single‐cell insights into the role of T cells in B‐cell malignancies
FEBS Letters, Volume 599, Issue 20, Page 2932-2951, October 2025.Single‐cell technologies have transformed our understanding of T cell–tumor cell interactions in B‐cell malignancies, revealing new T‐cell subsets, functional states, and immune evasion mechanisms. This Review synthesizes these findings, highlighting the roles of T cells in pathogenesis, progression, and therapy response, and underscoring their ...
Laura Llaó‐Cid
wiley +1 more source
Ibrutinib: a force with a dark side? [PDF]
Blood, 2016 In this issue of Blood, Martin et al report poor outcomes for ibrutinib-refractory patients with mantle cell lymphoma (MCL). MCL, an uncommon B-cell lymphoma driven by dysregulated cyclin D1, responds well to initial therapy but is destined to relapse.
openaire +3 more sources
FEBS Letters, Volume 599, Issue 20, Page 2954-2972, October 2025.Three‐dimensional (3D) biological systems have become key tools in lymphoma research, offering reliable in vitro and ex vivo platforms to explore pathogenesis and support precision medicine. This review highlights current 3D non‐Hodgkin lymphoma models, detailing their features, advantages, and limitations, and provides a broad perspective on future ...
Carla Faria +3 more
wiley +1 more source
miR-155 expression is associated with chemoimmunotherapy outcome and is modulated by Bruton’s tyrosine kinase inhibition with Ibrutinib [PDF]
, 2014 Daphne Guinn +11 more
openalex +1 more source
Cancer Medicine, Volume 14, Issue 20, October 2025.ABSTRACT Background CD19‐targeted chimeric antigen receptor‐T cell (CART19) therapy is clinically effective in patients with relapsed or refractory B‐cell lymphoma (BCL), but treatment failure and recurrence need to be overcome. Preclinical studies demonstrated that Bruton tyrosine kinase inhibitor (BTKi) improved the efficacy of CART19 therapy ...
Wenjing Luo +13 more
wiley +1 more source